

Foreword by Prof. Brenda Gallie


Finger's Essential Ophthalmic Oncology is an outstanding 2024 view of the whole field. Chapter One leads with full view of eye cancer, the common universal elements, social contexts, and looks forward to the new, rapidly emerging digital world. It recognizes the basis for continuous advancement in eye cancer care. The sharing of data globally was exemplified by The Eye Cancer Foundation's leadership, as Dr. Finger brought together world experts participating in the collection of registry data, and collaborative meetings to achieve the 7th edition AJCC-UICC TNM staging. This leadership went on to inspire a flurry of global surveys pulling data from centers around the world. Each points forward toward best outcomes.

The AJCC's decision to include heritable trait in Retinoblastoma staging will lead the whole cancer world. TNMH is today still unique for retinoblastoma, recognized since 1971 to be a cancer initiated by genomic changes. In 2024, public citizens have common knowledge that some cancers arise because of inherited risk, and that knowledge can achieve earlier diagnosis and improve cures. We anticipate that the 9th edition will be AJCC-UICC TNMH for all cancers.

Each chapter of Finger's Essential Ophthalmic Oncology is the careful work of expert teams, with references to the burgeoning collaborative global sharing of retrospective eye cancer treatments and outcomes. The digital world we now enjoy is exemplified in this content and format. The pdf is easy to search, read quietly or listen to, setting the stage for Finger's Essential Ophthalmic Oncology to be quickly at the service of Ocular Oncologists everywhere to find the best solutions for each patient seeking their care.

This book invites us to also use its excellent images to directly help patients understand their disease and embrace inclusive participation in key management decisions. Looking forward, those with lived experience may play key roles as patient advocates. The World Health Organization Global Initiative for Childhood Cancer has prioritized retinoblastoma as a key pediatric cancer indicator because of the profound inequity in survival depending on where the child lives. Finger's Essential Ophthalmic Oncology, combined with international multicenter collaboration in training of ocular oncologists,

supports development of regional centers. with support of experienced clinical and patient advocates. Just as retinoblastoma led all cancer genetics, Finger's Essential Ophthalmic Oncology provides a basis for locally developed, achievable guidelines that optimize care near home and achieve global cancer equity.



Prof. Brenda Gallie, MD, FRCSC, CM, OOnt

Director of the Retinoblastoma (RB) Program, The Hospital for Sick Children

Senior Scientist at the Ontario Cancer Institute, University Health Network and Professor of Ophthalmology, Molecular Genetics, and Medical Biophysics, University of Toronto, ON, Canada

